Where Could Canopy Growth (TSX:WEED) Be in 3 Years?

The future of Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) has become more uncertain after losing $1 billion in three months. Investors would like to see how the weed company rises from this fiasco before investing in the stock again.

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Is Canopy Growth (TSX:WEED)(NYSE:CGC) heading into freefall? The stock fell by 14.4% to $36.41 after the largest cannabis producer reported $1.28 billion losses in the first quarter of fiscal 2020 ended June 30, 2019. It was a far cry from the $90 million loss in Q1 of fiscal 2019.

Likewise, Canopy’s operating loss rose by 300.65% to $123 million in the June quarter compared with the same quarter a year ago. The latest earnings result is a sign that Canopy would not be profitable anytime soon.

The midterm future is very foggy for the once much-admired Canadian cannabis company. Canopy Growth’s board of directors, of which the majority are Constellation Brands-appointed, is now running the show.

Fallout  

If you were to predict the future of Canopy Growth three years down the road, you’d have to dig deep to find a silver lining. The company’s founder and former CEO Bruce Linton is out of the picture. But acting Chief Executive Mark Zekulin said they’re working behind the scenes.

The colossal loss doesn’t comprise cash but a mere accounting entry. Constellation Brands, Canopy’s business partner and significant shareholder, is delaying in order to exercise its warrants to buy shares of Canopy. The American beverage giant has so far shelled out $5.3 billion, but could buy more shares in 2020.

Canopy Growth still has $3.1 billion cash in its war chest as of June 30, so there is no urgency on Constellation Brands’ part to exercise the warrants. However, it’s not clear whether the Corona beer maker intends to acquire a majority stake in Canopy.

Canopy Growth’s sold $90.5 million worth of recreational and medical cannabis during the quarter; however, it fell short of the $109 million consensus estimate. In fairness, the average selling price for recreational marijuana declined from the March quarter. Sales of recreational marijuana accounted for 86% of the total.

The company is excited about the prospects of edibles and cannabis-infused beverages in Canada. Come December this year, Canopy Growth expects to see a rise in cannabis revenues and hopefully profit.

No more grand plans

Bruce Linton had ambitious dreams for Canopy Growth, and Constellation Brands bought into the idea by investing a fortune. Unfortunately, the excessive spending and mounting losses were too much to bear.

Canopy’s interim head Zekulin told investors that the multi-year period of intensive spending and building is almost over. The focus now is to evolve from builders to operators over the rest of this fiscal year.

It appears that the way to profitability is through the value-added products with a high margin. Management believes that the company would be a revenue machine in the edibles and cannabis-infused beverage market.

I can only say where Canopy Growth would be in three years after the next two quarterly earnings. With the cloud of uncertainty over the company, WEED will hit its 52-week low of $34.36 next then and sink deeper. The sell signals are strong.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »